Reading VIR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VIR free→Reading VIR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VIR free→QuarterlyIQ Insights · VIR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve o…
Director and Chair of the Audit Committee — Saira Ramasastry: Due to a business conflict, Ms. Ramasastry is stepping down from her role.
Results of Operations and Financial Condition. On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…
Importance-ranked changes since the prior daily snapshot.
Company momentum fell by 22.2 points (from -17.8 to -40.0).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.